Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 2/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | APLNR | P35414 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1249392 | 0.83 | NOS1 (0.39) | NOS1NOS3NOS2LTA4HSLC7A5 | |
| SCHEMBL14280531 | 0.83 | NOS1 (0.39) | NOS1NOS3NOS2LTA4HSLC7A5 | |
| SCHEMBL569252 | 0.82 | NOS1 (0.39) | NOS1NOS3NOS2LTA4HSLC7A5 | |
| SCHEMBL3294154 | 0.82 | NOS1 (0.42) | NOS1NOS3NOS2LTA4HSLC7A5 | |
| SCHEMBL12482643 | 0.81 | NOS1 (0.36) | NOS1NOS3NOS2LTA4HSLC7A5 | |
| SCHEMBL27475235 | 0.80 | NOS1 (0.34) | NOS1NOS3NOS2LTA4HSLC7A5 | |
| SCHEMBL31145590 | 0.80 | NOS1 (0.34) | NOS1NOS3NOS2LTA4HSLC7A5 | |
| SCHEMBL3211803 | 0.80 | NOS1 (0.37) | NOS1NOS3NOS2LTA4HSLC7A5 | |
| SCHEMBL186691 | 0.80 | NOS1 (0.38) | NOS1NOS3NOS2LTA4HSLC7A5 | |
| SCHEMBL1952044 | 0.80 | NOS1 (0.38) | NOS1NOS3NOS2LTA4HSLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113038943-B | Pharmaceutical composition | 生化学工业株式会社 | 2024-11-19 | — | — | CN | disclosed |
| CN-111902149-B | Hyaluronic acid synthesis promoter, method for promoting hyaluronic acid synthesis, and cell evaluation method | 生化学工业株式会社 | 2024-10-25 | — | — | CN | disclosed |
| US-20240252693-A1 | FOLATE RECEPTOR-TARGETED RADIOTHERAPEUTIC AGENTS AND THEIR USE | NOVARTIS PHARMACEUTICALS CORPORATION | 2024-08-01 | — | — | US | disclosed |
| EP-4389218-A2 | COMPOSITION FOR TREATING JOINT DISEASE AND KIT CONTAINING SAME | Seikagaku Corporation (JP) | 2024-06-26 | — | — | EP | disclosed |
| EP-3597198-B1 | COMPOSITION FOR TREATING JOINT DISEASES AND KIT INCLUDING SAME | SEIKAGAKU KOGYO CO LTD (JP) | 2024-06-12 | — | — | EP | disclosed |
| EP-4323017-A1 | FOLATE RECEPTOR-TARGETED RADIOTHERAPEUTIC AGENTS AND THEIR USE | Novartis AG (CH) | 2024-02-21 | — | — | EP | disclosed |
| CN-117427182-A | Composition for treating joint disease and kit containing same | 生化学工业株式会社 | 2024-01-23 | — | — | CN | disclosed |
| CN-117427183-A | Composition for treating joint disease and kit containing same | 生化学工业株式会社 | 2024-01-23 | — | — | CN | disclosed |
| CN-117083088-A | Folate receptor targeted radiotherapy agent and use thereof | 诺华股份有限公司 | 2023-11-17 | — | — | CN | disclosed |
| EP-3881841-B1 | PHARMACEUTICAL COMPOSITION | SEIKAGAKU KOGYO CO LTD (JP) | 2023-10-18 | — | — | EP | disclosed |
| WO-2003022219-A2 | BIARYLAMINO PURINE ANTIPROLIFERATIVE AGENTS | ALBANY MOLECULAR RESEARCH, INC. (US) | 2003-03-20 | — | — | WO | disclosed |
| WO-2003022805-A2 | HETEROCYCLE SUBSTITUTED PURINES AS ANTIPROLIFERATIVE AGENTS | ALBANY MOLECULAR RESEARCH, INC. (US) | 2003-03-20 | — | — | WO | disclosed |
| EP-1266896-A1 | Linear ou cyclic ureas, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2002-12-18 | — | — | EP | disclosed |
| US-20020091263-A1 | Biaryl substituted purine derivatives as potent antiproliferative agents | ALBANY MOLECULAR RESEARCH, INC. | 2002-07-11 | — | — | US | disclosed |
| EP-1218355-A1 | THERAPEUTIC QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2002-07-03 | — | — | EP | disclosed |
| US-20010009911-A1 | New linear or cyclic ureas | LES LABORATOIRES SERVIER (FR) | 2001-07-26 | — | — | US | disclosed |
| EP-1113014-A1 | Linear or cyclic ureas, a process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 2001-07-04 | — | — | EP | disclosed |
| WO-2001021597-A1 | THERAPEUTIC QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-03-29 | — | — | WO | disclosed |
| US-5908863-A | ANTIGROWTH AGENT FOR BONES | DOMPE' S.P.A. (IT) | 1999-06-01 | — | — | US | disclosed |
| EP-0792878-A2 | Geminal carboxylic acids and esters thereof, pharmaceutical formulations containing them useful in the treatment of bone dysmetabolism | Dompé S.P.A. (IT) | 1997-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010009911-A1 | New linear or cyclic ureas | GUCY1B1, UACA, LIPG | NOS1 115/4885NOS3 104/4885NOS2 246/4885 |
| US-20020091263-A1 | Biaryl substituted purine derivatives as potent antiproliferative agents | CCNA1, CCNA2, CDK2 | NOS1 3986/4885NOS3 4038/4885NOS2 4203/4885 |
| US-20240252693-A1 | FOLATE RECEPTOR-TARGETED RADIOTHERAPEUTIC AGENTS AND THEIR USE | FOLR1, FOLR2, FOLH1 | NOS1 4783/4885NOS3 4636/4885NOS2 4654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.